Mylan Sales Miss Mark Ahead of Tie-Up With Pfizer’s Upjohn
Photographer: Jeff Swensen/Getty Images
This article is for subscribers only.
Mylan NV reported lower-than-expected sales for the fourth quarter but projected revenue for the full year 2020 in line with Wall Street estimates, as the company prepares to combine with Pfizer Inc.’s off-patent drug unit Upjohn.
Mylan shares fell 1.1% in late trading on Thursday. Through the close of regular trading, the stock had fallen 7.1% year-to-date, hurt in part by a broader selloff in the stock market.